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smaller than 1.0 cm; the stage was IA in 5
patients and IIIA in 1 patient. For the entire
16 patients with ground-glass opacities, the
stage was IA in 13, IB in 1, and IIIA in 2.
Our report, however, only examined those
patients who underwent surgical interven-
tion, so it does not represent a complete
description of all patients in our CT screen-
ing trial with ground-glass opacities. We
eagerly await continued reporting from the
radiology literature about the entire spec-
trum of patients found to have ground-glass
opacity on a screening CT.
The question regarding computer-aided
diagnosis for enlargement of small nodules is
provocative. Three-dimensional computer-
aided diagnosis is clearly superior to 2-
dimensional human measurement. This
would be the preferred technique only when
it can be smoothly automated for efficient use
in day-to-day practice.1
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Why clopidogrel failed to inhibit
platelet function early after coronary
artery bypass surgery: To load or not
to load, and is it a question of
resistance?
To the Editor:
Antiplatelet therapy remains a topic of
much-deserved attention and debate. We
read with interest the recent article by Lim
and associates1 in which they found that
clopidogrel after coronary artery bypass
grafting failed to inhibit platelet function,
on the basis of the percentage platelet ag-
gregation on day 5. Patients were random-
ized to receive 100 or 325 mg of aspirin
daily or 75 mg of clopidogrel daily for 5
days after coronary artery bypass grafting.
It is not clear whether patients in the clo-
pidogrel arm received a loading dose be-
fore the daily maintenance dose. Several
similar studies assessing platelet inhibition,
albeit in the context of percutaneous coro-
nary intervention, have demonstrated the
importance of appropriate loading of 300 to
600 mg if steady-state levels of platelet
aggregation are to be achieved within the
first 24 hours.2-4 Daily maintenance dosing
with 75 mg of clopidogrel without preload-
ing, as in this study, has been shown to
result in steady-state levels of platelet in-
hibition only after 3 to 7 days.5
The second observation with regard to
this study is that the investigators did not
state whether a baseline pretreatment sam-
ple was taken before surgery or before ad-
ministration of the antiplatelet therapy.
Whether this would have added much to
the final analysis remains unclear, but evi-
dence, again drawn from studies in the
percutaneous coronary intervention setting,
have suggested pretreatment platelet reac-
tivity to be an important determinant of
posttreatment reactivity.6
The final comment is the most elusive,
namely, the issue of “clopidogrel resis-
tance.” Although it was not directly men-
tioned by the authors, we can assume that it
was alluded to in their discussion. It is
likely that a correlation exists between a
laboratory measure of clinical clopidogrel
nonresponsiveness and the clinical out-
come. However, until such time as there is
greater understanding of the likely mecha-
nisms of clopidogrel responsiveness and the
individual heterogeneity that is apparent, can
we totally dismiss the efficacy of clopidogrel
in the early postoperative period?
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Reply to the Editor:
In our reply to Raja, we have addressed a
similar query with regard to the dosing
regimen of clopidogrel. It is vitally impor-
tant to appreciate that the study in which
Hunt and associates quote the time to the
onset of the effects of clopidogrel (4 to 7
days) is from a sample of healthy subjects.1
Nonrandomized studies after coronary ar-
tery bypass surgery suggest that it takes 9
to 28 days.2 Our results are consistent with
the latter.
In our article, you will note that we
reported all measurements as the percent-
age change compared with baseline.3 The
baseline sample was taken on the day be-
fore surgery.
We respectfully disagree with the final
comment of Hunt. A previous observa-
tional study and our randomized data are
consistent regarding the inefficacy of clo-
pidogrel early after coronary surgery as-
sessed on aggregometry. At present, we are
unaware of any evidence to the contrary;
therefore, the onus should be to prove that
an effect exists before prescribing clopi-
dogrel (as the sole antiplatelet in this time
frame), rather than subjecting patients to
the possibility of ineffective treatment
while awaiting a “greater understanding of
the likely mechanisms of clopidogrel re-
sponsiveness.”
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Aortic dissection and ankylosing
spondylitis in hypocystinemia
To the Editor:
The first author and past associates recently
described aortic dissection without Marfan
syndrome in ankylosing spondylitis,1 and
coexistent ankylosing spondylitis and
Marfan syndrome without aortic dissection
has been reported in the literature.2 Re-
duced fibrillin deposition into the extracel-
lular matrix is found in not only Marfan
syndrome but also in a range of connective
tissue disorders collectively termed fibrilli-
nopathies, such as isolated ascending aortic
aneurysm and dissection.3 The defective
fibrillin of Marfan microfibrils and the
inflammation-targeted fibrillin of ankylos-
ing spondylitis might each lead to compa-
rable structural phenotypes of failure.4 On
the other hand, fibrillin-1 is rich in cys-
teine, and its deposition into the extracel-
lular matrix is greatly diminished under
conditions of cysteine deficiency.5 We
here add another case, with hypocystine-
mia, of coexistent aortic dissection and
ankylosing spondylitis, and discuss pos-
sible roles of cyst(e)ine and fibrillin-1 in
these 2 disorders.
A 68-year-old woman with back pain
was referred to our department. Computed
tomographic scanning disclosed Stanford
type A (DeBakey type I) acute aortic dis-
section (Figure 1, A), but she presented
with no traits of Marfan syndrome on phys-
ical examination. Urgent replacement of
the ascending aorta was successfully per-
formed, and the pathologic examination of
the aortic wall revealed neither aortitis nor
cystic medial necrosis. Plasma total homo-
cysteine concentration was normal (4.7
nmol/mL [range, 3.0-14 nmol/mL]), and
cystine concentration was decreased to
14.5 nmol/mL (range, 29-49 nmol/mL).
There was a past history of ankylosing
spondylitis without medication, including
steroids, and abdominal radiography dis-
closed the characteristic deformation of the
lumbar vertebrae, so-called bamboo spine
(Figure 1, B). The patient had negative
results for human leukocyte antigen B27
but met the European Spondylarthropathy
Study Group preliminary criteria for the
classification of spondylarthropathy: in-
flammatory spinal pain, alternate buttock
pain, and sacroiliitis.
Reduced fibrillin deposition into the ex-
tracellular matrix causes thoracic aortic aneu-
rysm or dissection in patients without Marfan
syndrome.3 Most sites of inflammation in
patients with ankylosing spondylitis involve
fibrocartilage, and fibrillin-1, a major compo-
nent of the microfibrils in fibrocartilage,
might be the target of this response in the
aorta and the eye, as well as in bones and
joints.4 It has been hypothesized that spondy-
litic inflammation might include release and
activation of latent transforming growth fac-
tor  from binding sites on fibrillin-1. The
hypothesis is supported by some reported
cases, including the present one, of coexistent
ankylosing spondylitis and Marfan syndrome
without aortic dissection2 or coexistent aortic
dissection without Marfan syndrome and an-
kylosing spondylitis.1 On the other hand, it
has been demonstrated that fibrillin-1 depo-
sition into the extracellular matrix was
greatly diminished, as revealed by means of
immunocytochemistry, when arterial smooth
muscle cells were cultured under conditions
of cysteine deficiency.5 When cysteine con-
centrations were returned to normal, the
smooth muscle cells began to accumulate a
matrix rich in fibrillin-1. These results indi-
cate that a deficiency of cysteine impairs the
accumulation of fibrillin-1 in the extracellular
matrix and could contribute to the pathologic
changes of connective tissue. Although the
cause of hypocystinemia in the present case
is unclear, a possible role of fibrillin-1 af-
fected by decreased cyst(e)ine is suggested in
coexistent aortic dissection and ankylosing
spondylitis.
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Figure 1. Computed tomographic scanning
disclosed Stanford type A (DeBakey type I)
acute aortic dissection (A). Abdominal ra-
diography revealed the characteristic de-
formation of the lumbar vertebrae, so-
called bamboo spine (B).
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